PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe.
- DOI
- 10.1093/jnci/djag322
- Published
- 2026 Sep 11
- Container
- Journal of the National Cancer Institute
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/jnci/djag322,
title = {PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe.},
author = {Basch E and Reaney M and Roydhouse J and King-Kallimanis BL and Sekoni D and Buzaglo J and Casamayor M and Caruano R and Chen CI and Quek RGW and Mastey V and Harnett J and Chi L},
year = {2026},
journal = {Journal of the National Cancer Institute},
doi = {10.1093/jnci/djag322},
url = {https://doi.org/10.1093/jnci/djag322}
}RIS
TY - JOUR TI - PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe. AU - Basch E AU - Reaney M AU - Roydhouse J AU - King-Kallimanis BL AU - Sekoni D AU - Buzaglo J AU - Casamayor M AU - Caruano R AU - Chen CI AU - Quek RGW AU - Mastey V AU - Harnett J AU - Chi L PY - 2026 JO - Journal of the National Cancer Institute DO - 10.1093/jnci/djag322 UR - https://doi.org/10.1093/jnci/djag322 ER -
APA
E, B., M, R., J, R., BL, K., D, S., J, B., M, C., R, C., CI, C., RGW, Q., V, M., J, H., & L, C. (2026). PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag322
Source records
- pubmed · retrieved 2026-09-25T12:54:57.515Z